Joanna Rostkowska1,2, Piotr Henryk Skarzynski2,3,4,5,6, Joanna Kobosko7, Elzbieta Gos3, Henryk Skarzynski6. 1. Rehabilitation Clinic, World Hearing Center, Institute of Physiology and Pathology of Hearing, Kajetany, Warsaw, Poland. 2. Department of Special Education, The Maria Grzegorzewska University, Szczęśliwicka 40, 02-353, Warszawa, Poland. 3. Teleaudiology and Screening Department, World Hearing Center, Institute of Physiology and Pathology of Hearing, Kajetany, Warsaw, Poland. 4. Faculty of Medicine, Heart Failure and Cardiac Rehabilitation Department, Medical University of Warsaw, Warsaw, Poland. 5. Institute of Sensory Organs, Kajetany, Warsaw, Poland. 6. Oto-Rhino-Laryngology Surgery Department, World Hearing Center, Institute of Physiology and Pathology of Hearing, Kajetany, Warsaw, Poland. 7. Experimental Audiology Department, Institute of Physiology and Pathology of Hearing, Warsaw, Poland. j.rostkowska@ifps.org.pl.
Abstract
PURPOSE: In clinical trials and everyday medical practice, health-related quality of life (HRQoL) measures are increasingly being used. That is, in addition to the usual biological health assessment, the impact of disease and treatment on the patient's functioning in the physical, mental, and social areas is an important parameter. The aim of this study was to assess HRQoL before and after using a cochlear implant (CI) in adults with profound hearing loss. METHODS: There were 104 patients who qualified for the study. All gave informed and free consent. The study involved adults with bilateral hearing loss above 81 dB HL and rated according to the World Health Organization (WHO) classification scheme as having profound hearing loss (which includes deafness). In each participant, the hearing loss was postlingual, that is, it occurred after speech and language had developed. The assessment of quality of life (AQoL-8D) questionnaire was used to assess the health-related quality of life in the study participants. RESULTS: Quality of life significantly increased (p < 0.001) after cochlear implantation in almost all domains (except the pain dimension). The mean increase in overall quality of life was 0.16, the greatest improvement was found in the dimensions senses (mean change of 0.17) and self-worth (mean change of 0.16). CONCLUSION: Cochlear implantation improves the health-related quality of life of the postlingually deaf.
PURPOSE: In clinical trials and everyday medical practice, health-related quality of life (HRQoL) measures are increasingly being used. That is, in addition to the usual biological health assessment, the impact of disease and treatment on the patient's functioning in the physical, mental, and social areas is an important parameter. The aim of this study was to assess HRQoL before and after using a cochlear implant (CI) in adults with profound hearing loss. METHODS: There were 104 patients who qualified for the study. All gave informed and free consent. The study involved adults with bilateral hearing loss above 81 dB HL and rated according to the World Health Organization (WHO) classification scheme as having profound hearing loss (which includes deafness). In each participant, the hearing loss was postlingual, that is, it occurred after speech and language had developed. The assessment of quality of life (AQoL-8D) questionnaire was used to assess the health-related quality of life in the study participants. RESULTS: Quality of life significantly increased (p < 0.001) after cochlear implantation in almost all domains (except the pain dimension). The mean increase in overall quality of life was 0.16, the greatest improvement was found in the dimensions senses (mean change of 0.17) and self-worth (mean change of 0.16). CONCLUSION: Cochlear implantation improves the health-related quality of life of the postlingually deaf.
Entities:
Keywords:
AQoL-8D questionnaire; Cochlear implant; Health-related quality of life; Postlingual hearing loss
Authors: Luis Lassaletta; Alejandro Castro; Marta Bastarrica; Maria José de Sarriá; Javier Gavilán Journal: Eur Arch Otorhinolaryngol Date: 2005-07-16 Impact factor: 2.503
Authors: A Ciorba; S Hatzopoulos; C Bianchini; C Aimoni; H Skarzynski; P H Skarzynski Journal: Int J Immunopathol Pharmacol Date: 2015-03 Impact factor: 3.219
Authors: Piotr H Skarzynski; Lukasz Olszewski; Artur Lorens; Andrzej W Wlodarczyk; Henryk Skarzynski Journal: Audiol Neurootol Date: 2015-02-20 Impact factor: 1.854
Authors: Peter Blamey; Françoise Artieres; Deniz Başkent; François Bergeron; Andy Beynon; Elaine Burke; Norbert Dillier; Richard Dowell; Bernard Fraysse; Stéphane Gallégo; Paul J Govaerts; Kevin Green; Alexander M Huber; Andrea Kleine-Punte; Bert Maat; Mathieu Marx; Deborah Mawman; Isabelle Mosnier; Alec Fitzgerald O'Connor; Stephen O'Leary; Alexandra Rousset; Karen Schauwers; Henryk Skarzynski; Piotr H Skarzynski; Olivier Sterkers; Assia Terranti; Eric Truy; Paul Van de Heyning; Fréderic Venail; Christophe Vincent; Diane S Lazard Journal: Audiol Neurootol Date: 2012-10-19 Impact factor: 1.854
Authors: Magdalena Beata Skarżyńska; Piotr Henryk Skarżyński; Bartłomiej Król; Magdalena Kozieł; Kamila Osińska; Elżbieta Gos; Henryk Skarżyński Journal: Med Sci Monit Date: 2018-04-22